Can you take Resveratrol and Pterostilbene together?

The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

Rankings / Comparisons

Resveratrol vs Pterostilbene

Resveratrol vs its methylated cousin — bioavailability, dose, and what the human trials actually show.

Reviewed by Read Off Label · How we grade

Score comparison

Resveratrol has the higher descriptive composite (B-, 6.2/10) compared with Pterostilbene (C-, 4.5/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.

Resveratrol

B- 6.2/10

Evidence: Weak-Moderate (4.5/10)
Benefit: Low-Med (3.5/10)
Risk: Low (9/10 safety)
Legality: OTC
Dose / route context: 150-500 mg/day trans-resveratrol; micronized formulations and co-administration with fat appear in absorption studies
Class: Supplement
Last reviewed: Jul 11, 2026

Read Off Label grades Resveratrol as B- (6.2/10) based on weak-moderate evidence, low-med benefit magnitude, and a low-risk safety profile.

Oft-cited as foundational longevity compound but human RCTs largely unimpressive.

Studied, labeled, or reported-use context: 150-500 mg/day trans-resveratrol; micronized formulations and co-administration with fat appear in… — OTC; not individualized guidance.

What it is

Oft-cited as foundational longevity compound but human RCTs largely unimpressive. Poor bioavailability (~1%). Metabolites may be active. 2025 meta-analysis: no significant SIRT1 effect in humans. Popularity persists despite modest signals.

Mechanism

Trans-resveratrol proposed SIRT1 activator (debated — likely indirect); AMPK activation; anti-inflammatory; vascular endothelial effects; poor oral bioavailability

Full Resveratrol review →

Pterostilbene

C- 4.5/10

Evidence: Weak-Preclinical (2.5/10)
Benefit: Low-Med / Varies (3.5/10)
Risk: Low-Med (LDL elevation reported) (7/10 safety)
Legality: OTC
Dose / route context: 50-250 mg/day
Class: Supplement
Last reviewed: Jun 8, 2026

Read Off Label grades Pterostilbene as C- (4.5/10) based on weak-preclinical evidence, low-med / varies benefit magnitude, and a low-med-risk safety profile.

Paired with NR in EH301 trial — modest ALS functional improvement.

Studied, labeled, or reported-use context: 50-250 mg/day — OTC; not individualized guidance.

What it is

Paired with NR in EH301 trial — modest ALS functional improvement. Better absorbed than resveratrol in theory but limited direct head-to-head human data. Often combined with nicotinamide riboside (e.g., Basis, Niagen+).

Mechanism

Dimethylated resveratrol analog; better oral bioavailability (~80% vs 1%); SIRT1 activator; AMPK activator; anti-inflammatory

Full Pterostilbene review →

Common questions

How do the evidence profiles of Resveratrol and Pterostilbene compare?: Resveratrol has the higher descriptive composite (B-, 6.2/10) compared with Pterostilbene (C-, 4.5/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
What's the difference between Resveratrol and Pterostilbene?: Resveratrol vs its methylated cousin — bioavailability, dose, and what the human trials actually show.
Can you take Resveratrol and Pterostilbene together?: The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

This is an independent synthesis of published research by a non-clinician. The comparison reports composite and axis-level differences without selecting an intervention for the reader. Relevance depends on indication, population, dose, duration, and other context. See the full disclaimer and methodology.